ML 145

• Description :

  ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) [1]. ML 145 has no significant activity for GPR35 at either rodent ortholog[2].

• UNSPSC :

  12352005

• Target :

  CXCR; GPR35

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Inflammation/Immunology; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/ml-145.html

• Purity :

  96.09

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CC(/C=C(S1)/C(N(CCCC(NC2=CC(O)=C(C(O)=O)C=C2)=O)C1=S)=O)=C\C3=CC=CC=C3

• Molecular Formula :

  C24H22N2O5S2

• Molecular Weight :

  482.57

• References & Citations :

  [1]Heynen-Genel S, et al. Selective GPR35 Antagonists - Probes 1 & 2. National Center for Biotechnology Information (US) ; 2010-2010 Feb 28.|[2]Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343 (3) :683-95.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1164500-72-4]